Since 1994, Abbott has been at the forefront of viral surveillance, with an unwavering commitment to monitor emerging and changing infectious diseases. As the only provider of infectious disease solutions with this large-scale Global Viral Surveillance Program, our mission is driven by two guiding principles:
Viral genetic diversity has the potential to impact a vast number of healthcare touchpoints.2 Viral surveillance helps ensure laboratory tests continue to accurately detect divergent viruses regardless of where they are acquired.
The Abbott Global Viral Surveillance Program pathway is fueled by collaboration, enabling us to proactively evaluate and solve infectious disease challenges.
In a recent collaboration with leading healthcare institutions, we discovered a novel, highly-divergent pathogen in a sample from an HCV-infected patient who died from sepsis and multi-organ failure of unknown etiology that was undetectable using conventional testing methods – second human pegivirus (HPgV-2).3
Abbott is the only diagnostic manufacturer in the world to conduct a program of this magnitude and length of time. To date, we have collected over 70,000 samples containing HIV and hepatitis viruses creating one of the largest libraries of its kind in the world, and we’ve deposited more than 6,000 sequences into the GenBank® database. Our discoveries have also resulted in over 125 publications.3-6
Take a look at some of our recent publications that reveal unique insights into local epidemiologies and highlight some of our discoveries. See how the work of the Abbott Global Viral Surveillance Program plays a significant role in challenging our on-market tests and looks ahead for new challenges with innovative research tools.
Abbott researchers work with cutting edge technologies and collaborate with leading hospitals and organizations worldwide to test diverse specimens that carry viruses that may cause deadly diseases. In fact, Abbott is only 1 of 2 institutions in the world to have identified and characterized rare HIV Group N and P viruses.1,6,7
Abbott partners with laboratories and organizations in 45 countries around the world, represented by the yellow triangles on the map below. The red triangles denote Abbott Global Surveillance sites.
Decades of global surveillance research and ongoing vigilance consistently fuel Abbott’s next generation of infectious disease solutions.
Connecting our global network of partnerships and making significant contributions to the scientific and medical community
Using a unique collection of samples to challenge reliability of Abbott on-market tests
Building the foundation for development of leading edge solutions that healthcare professionals and patients can trust
Are you looking into the epidemiology, prevalence or diversity of HIV and hepatitis viruses? If you are an investigator from a research, clinical or blood banking institution and have a project you want to collaborate on, contact us. Learn how we can discover, publish and innovate together.
Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott. The website that you have requested also may not be optimised for your screen size.
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.
